StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) to a sell rating in a research note issued to investors on Monday.
Separately, Needham & Company LLC reissued a hold rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, April 11th.
Get Our Latest Stock Analysis on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Trading Down 4.4 %
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last issued its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.03. The company had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. As a group, equities analysts forecast that Lexicon Pharmaceuticals will post -0.71 EPS for the current year.
Institutional Investors Weigh In On Lexicon Pharmaceuticals
A number of institutional investors have recently modified their holdings of LXRX. BVF Inc. IL raised its stake in Lexicon Pharmaceuticals by 22.2% during the fourth quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock worth $37,387,000 after buying an additional 4,440,300 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Lexicon Pharmaceuticals by 34.0% in the 3rd quarter. Vanguard Group Inc. now owns 5,256,288 shares of the biopharmaceutical company’s stock worth $12,614,000 after acquiring an additional 1,334,318 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 27.4% in the 3rd quarter. BlackRock Inc. now owns 5,760,000 shares of the biopharmaceutical company’s stock valued at $13,823,000 after purchasing an additional 1,240,171 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $1,194,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at about $1,155,000. 74.70% of the stock is owned by institutional investors.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
See Also
- Five stocks we like better than Lexicon Pharmaceuticals
- Insider Buying Explained: What Investors Need to Know
- United Airlines Soars on Earnings Beat
- What Makes a Stock a Good Dividend Stock?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What is the Euro STOXX 50 Index?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.